Pharmaxis to Present at Proactive CEO Investor Session
Release Date: 10/11/2020 8:30am
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present at the Proactive CEO Investor Session to be held today, Tuesday 10 November 2020. Mr Phillips will discuss the significance of last week’s US FDA approval of Bronchitol for Pharmaxis and the Company’s focus on its new drug for the bone cancer myelofibrosis that will commence a phase 1c/2 clinical trial next quarter.
The program commences at 12.00 noon (AEST) and will feature fifteen minute presentations from the CEO’s of three companies – Pharmaxis Ltd, Cynata Therapeutics Ltd and Recce Pharmaceuticals Ltd.
Shareholders and investors are invited to participate in this free event. Please register at the Proactive website at https://www.proactiveinvestors.com.au/register/event_details/298#
A recording of the Investor Session will be made available on the Pharmaxis website after the event.
Categories: News and Media